MDT · NYSE · CIK 0001613103
Medtronic plc
Medtronic plc holds 1 disclosed position, 0 of them carrying a sourced value and 1 that nobody has sized.
Share price
MDT
Equity stakes Medtronic plc holds in other companies.
No position on this side carries a sourced value, so there is nothing to chart. The table still lists 1 of them.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 2,195 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
2,195 managers reported a position, together holding 1.09bn shares, or 85.4% of the company. The 40 largest are listed.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Medtronic plc is Irish-domiciled with a fiscal year ending in late April; its FY2026 Form 10-K (period ended 24 April 2026) was filed 18 June 2026 and is the most recent SEC filing overall, more recent than the last 10-Q (filed 24 Feb 2026, for the quarter ended 23 January 2026). The EDGAR submissions feed for CIK 0001613103 (checked 17 August 2026) shows no subsequent 10-Q, consistent with Medtronic's FY2027 Q1 10-Q not yet being due.
- shares_outstanding (1,280,045,190) is the FY2026 10-K cover-page count as of 12 June 2026, the freshest company-reported share count available. Register rows use different, closer-in-time denominators where a fresher one exists for that holder's as_of date (see each row's pct_denominator); this mirrors the reconciliation approach used in the waste-management.json reference file.
- Medtronic does not file Form 13F under CIK 0001613103. The EDGAR submissions feed contains no 13F-HR or 13F-NT of any vintage among its form types, consistent with Medtronic being an operating company rather than an institutional investment manager.
- Vanguard's most recent 13F-HR under CIK 0000102909 with actual holdings covers the quarter ended 31 December 2025 (filed 29 Jan 2026); Vanguard filed only notice-only Form 13F-NT (no information table) for the quarters ended 31 March 2026 (filed 8 May 2026) and 30 June 2026 (filed 13 Aug 2026), so no fresher Vanguard share count is available from that CIK. All other institutional register rows use each filer's 13F-HR for the quarter ended 30 June 2026, filed in early-to-mid August 2026.
- The FY2026 10-K's 'Equity Securities, Equity Method Investments, and Other Investments' note reports a combined $824 million total at 24 April 2026 ($951 million at 25 April 2025), split by ACCOUNTING CATEGORY, not by investee: investments with readily determinable fair value (marketable equity securities) $130m; investments for which the fair value option has been elected $0 ($140m in FY2025); investments without readily determinable fair values (measurement alternative: cost minus impairment) $616m ($705m in FY2025); equity method and other investments $78m ($89m in FY2025). Per the brief, a combined balance sizes no single investee, so only the one investee the filing names directly (Mozarc Medical, see holdings) is recorded; the $616m and $78m buckets, which almost certainly contain Medtronic's minority corporate-venture stakes in medtech startups, name no individual investee anywhere in the filing and are recorded here rather than split.
- Mozarc Medical's fair value is inferred to sit in the 'investments for which the fair value option has been elected' category: that category's balance fell from $140m (FY2025) to exactly $0 (FY2026), matching the 10-K's dedicated Mozarc note, which states cumulative losses (including $140m recognized in fiscal year 2026 alone) 'reduc[ed] the fair value of the investment to zero as of the end of fiscal year 2026'.
- CathWorks was a separate, previously-held 15% equity interest (plus a debt investment and an option on the remaining 85%). Medtronic exercised its option and acquired the remaining 85% on 3 February 2026, making CathWorks a wholly owned subsidiary by fiscal year end; it is therefore excluded from holdings per the brief (wholly owned operating subsidiary), not recorded as a minority stake.
- Medtronic has a single class of ordinary shares, $0.0001 par value, one vote per share; there is no dual-class structure and no founder control block. CEO Geoffrey S. Martha's insider position (0.15% of shares outstanding) is not individually or collectively a control stake.
- The 2025 DEF 14A (filed 25 Aug 2025, for the AGM held 16 Oct 2025) is the latest proxy statement; a newer proxy for the autumn 2026 AGM was not yet filed as of 17 August 2026. The proxy's own 'Security Ownership' table lists only Vanguard (9.72%) and BlackRock (9.41%) as >5% holders, each sourced by the proxy itself to each manager's Schedule 13F for the quarter ended 30 June 2025; the register above instead uses each manager's own, more recent 13F-HR filings.
- Market capitalization ($116.83 billion) and the current share price ($91.27) are stockanalysis.com's reported figures as of 14 August 2026 close (aggregator basis); cross-check: 1,280,045,190 shares x $91.27 implies approximately $116.83 billion, consistent.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Whether any specific, named company sits inside the FY2026 10-K's $616 million 'investments without readily determinable fair values' bucket or its $78 million 'equity method and other investments' bucket. Searched the FY2026 10-K's investments note and the MD&A for 'equity method', 'non-marketable', 'nonmarketable', 'measurement alternative', 'strategic investment', 'minority investment', 'equity securities', 'cost method', and 'unrealized gain'; the only investee named anywhere in the filing is Mozarc Medical (recorded in holdings) and CathWorks (now wholly owned, excluded). Medtronic's corporate-venture minority stakes in medtech startups referenced generically via 'minority investments' gain/loss lines in non-GAAP reconciliations are not individually named.
- The exact identities of the 2 unnamed current executive officers included in the proxy's 'Directors and executive officers as a group (18 persons)' row but not individually listed in its beneficial ownership table (16 named rows for directors and Summary Compensation Table officers).
- Medtronic's FY2027 Q1 10-Q (covering the quarter ending on or about 24 July 2026) was not yet filed as of 17 August 2026 per the EDGAR submissions feed for CIK 0001613103; any equity position or CathWorks/Mozarc valuation change since 24 April 2026 would not yet be visible.
- No sovereign wealth fund position (e.g. Norges Bank) could be sourced within the time budget; sovereign funds typically hold via non-13F index mandates outside the US.
- Capital Group / Capital Research International's and T. Rowe Price's 13F positions were not looked up individually within the time budget; only the seven managers named in the brief (Vanguard, BlackRock, State Street, Geode, FMR, Morgan Stanley, JPMorgan) plus the proxy's 5-percent-and-above and top named insider disclosures were pulled for the register.